Hot Topic: Targeted Therapy
In this video, Anshu Giri, MD, MS, assistant professor of oncology at the Fox Chase Cancer Center, discusses:
- the effectiveness of recent FDA approvals, including trastuzumab deruxtecan (Enhertu; AstraZeneca, Daiichi Sankyo) and olaparib (Lynparza; AstraZeneca, Merck);
- updates on clinical trials in triple negative breast cancer (EMBRACA, ASCENT, KEYNOTE 355);
- tactics in managing resistance to targeted therapies and adverse events;
- unmet needs in targeted therapies; and
- how resistance to targeted therapies may change the course of treatment.